394 related articles for article (PubMed ID: 27775715)
1. Design and characterization of bivalent BET inhibitors.
Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective bivalent inhibitors of BET bromodomains.
Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
4. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
5. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
6. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
[TBL] [Abstract][Full Text] [Related]
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
9. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
10. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
11. What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?
Yao D; Liu J; Ouyang L
Future Med Chem; 2017 Jun; 9(9):839-842. PubMed ID: 28635318
[No Abstract] [Full Text] [Related]
12. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
13. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
14. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
15. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
16. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
Jones Lipinski RA; Stancill JS; Nuñez R; Wynia-Smith SL; Sprague DJ; Nord JA; Bird A; Corbett JA; Smith BC
Am J Physiol Regul Integr Comp Physiol; 2024 Jun; 326(6):R515-R527. PubMed ID: 38618911
[TBL] [Abstract][Full Text] [Related]
17. BET inhibition as a new strategy for the treatment of gastric cancer.
Montenegro RC; Clark PG; Howarth A; Wan X; Ceroni A; Siejka P; Nunez-Alonso GA; Monteiro O; Rogers C; Gamble V; Burbano R; Brennan PE; Tallant C; Ebner D; Fedorov O; O'Neill E; Knapp S; Dixon D; Müller S
Oncotarget; 2016 Jul; 7(28):43997-44012. PubMed ID: 27259267
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
[TBL] [Abstract][Full Text] [Related]
19. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
[TBL] [Abstract][Full Text] [Related]
20. An Overview on Small Molecule Inhibitors of BRD4.
Huang W; Zheng X; Yang Y; Wang X; Shen Z
Mini Rev Med Chem; 2016; 16(17):1403-1414. PubMed ID: 27290915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
